细胞色素P4502A6基因多态性与来曲唑药代动力学和药效学的相关性研究

Relationship between genetic polymorphisms of CYP2A6 and pharmacokinetics and pharmacodynamics of letrozole

来曲唑作为第3代芳香化酶抑制剂,已被广泛应用于抗妇科肿瘤领域。临床上有诸多因素影响来曲唑的药代动力学及药效学,其中,细胞色素P4502A6(CYP2A6)基因多态性是造成来曲唑个体间差异的重要因素之一。本文综合国内外报道,阐述CYP2A6基因多态性与来曲唑药代动力学、药效学相关性的研究现状,为制定来曲唑的个体化用药方案提供一定的参考。

As one of the third generation of aromatase inhibitors,letrozole has already been widely used in the field of gynecological oncology.Its process and pharmacodynamics are affected by many factors,such as genetic polymorphism of CYP2A6 which could lead to significant individual differences. To offer guidance for individualized administration of letrozole,this article specifies the relationship between genetic polymorphisms of CYP2A6 and the pharmacokinetics and pharmacodynamics of letrozole.